NCT01623401View on ClinicalTrials.gov

A Phase 1, Open-Label, 10 Day Safety Study

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 17, 2012

Primary Completion Date

August 24, 2012

Study Completion Date

August 24, 2012

Conditions
Healthy Subjects
Interventions
DRUG

TR-701 FA

TR-701 FA 200 mg once daily

Trial Locations (1)

75247

Trius Investigator Site 001, Dallas

All Listed Sponsors
lead

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT01623401 - A Phase 1, Open-Label, 10 Day Safety Study | Biotech Hunter | Biotech Hunter